epidermal growth factor receptor dual-targeting chimeric antigen receptor natural killer cells

Epidermal growth factor receptor dual-targeting chimeric antigen receptor natural killer cells are an **investigational CAR-NK cell therapy** designed to recognize **EGFR** as one of two intended tumor antigens and mediate direct NK-cell cytotoxicity against antigen-expressing cancer cells. The exact paired second target, CAR architecture, cellular source, and sponsoring company are not uniquely identifiable from the queried name alone, making this a non-proprietary descriptive label rather than a clearly defined single product. In available recent trial-style records and related literature, dual-target CAR-NK approaches involving EGFR have been explored primarily for **solid tumors**, including **glioblastoma/high-grade glioma** and **non-small cell lung cancer**, with the therapeutic rationale of reducing antigen-escape and improving activity in heterogeneous EGFR-positive tumors.

Other names

epidermal growth factor receptor dual-targeting chimeric antigen receptor natural killer cellsEGFR dual-targeting CAR-NK cellsdual-targeting CAR-NK cells targeting EGFR